This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, non-eHealth) (208) Health Services Research (570) Aging with Chronic Disease (184) Diabetes Self-Management (606) Precision Medicine (173)

Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/62667, first published .
Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial

Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial

Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial

Authors of this article:

Tiffany M Cortes1, 2, 3 Author Orcid Image ;   Libia Vasquez4 Author Orcid Image ;   Monica C Serra2, 3, 5 Author Orcid Image ;   Ronna Robbins6 Author Orcid Image ;   Allison Stepanenko2 Author Orcid Image ;   Kevin Brown2 Author Orcid Image ;   Hannah Barrus2 Author Orcid Image ;   Annalisa Campos2 Author Orcid Image ;   Sara E Espinoza5, 7, 8 Author Orcid Image ;   Nicolas Musi7, 8 Author Orcid Image
Article Authors Cited by (9) Tweetations Metrics

Journals

  1. Karakasis P, Patoulias D, Fragakis N, Mantzoros C. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism 2025;164:156113 View
  2. Espinoza S, Broder J, Wolfe R, Ernst M, Shah R, Orchard S, Woods R, Ryan J, Murray A. Frailty incidence by diabetes treatment regimens in older adults with diabetes mellitus in the ASPirin in Reducing Events in the Elderly Study. GeroScience 2025;47(3):5169 View
  3. Miousse I. GLP-1 receptor agonists in the context of cancer: the road ahead. American Journal of Physiology-Cell Physiology 2025;328(6):C1822 View
  4. Koceva A, Janež A, Jensterle M. Impact of Incretin-Based Therapy on Skeletal Muscle Health. Medicina 2025;61(9):1691 View
  5. Dinkla L, Beavers K, Robbins R, Akpalu D, Wherry S, Miller G, Beavers D, Espinoza S, Trejo J, Stepanenko A, Cortes T. Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial post hoc analysis. Frontiers in Aging 2025;6 View
  6. Chrysavgis L, Mourelatou N, Koloutsou M, Rozani S, Cholongitas E. The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition. International Journal of Molecular Sciences 2025;26(24):12130 View
  7. Ábel T, Csobod Csajbókné É. Semaglutide-Mediated Remodeling of Adipose Tissue in Type 2 Diabetes: Molecular Mechanisms Beyond Glycemic Control. International Journal of Molecular Sciences 2026;27(3):1186 View
  8. Prokopidis K. Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions. British Journal of Pharmacology 2026 View
  9. Alourfi N, Alorfi N. GLP-1 Receptor Agonist Therapy in Older Adults with Diabetes: A Qualitative Analysis of Phase 4 ClinicalTrials.gov Studies. Diabetes, Metabolic Syndrome and Obesity 2026;Volume 19:1 View